Order Article Reprints

Herbreteau G, Langlais A, Greillier L, Audigier-Valette C, Uwer L, Hureaux J, Moro-Sibilot D, Guisier F, Carmier D, Madelaine J, et al. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. Journal of Clinical Medicine. 2020; 9(12):3861. https://doi.org/10.3390/jcm9123861

Herbreteau, Guillaume, Alexandra Langlais, Laurent Greillier, Clarisse Audigier-Valette, Lionel Uwer, José Hureaux, Denis Moro-Sibilot, Florian Guisier, Delphine Carmier, Jeannick Madelaine, and et al. 2020. "Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab" Journal of Clinical Medicine 9, no. 12: 3861. https://doi.org/10.3390/jcm9123861

Herbreteau, G., Langlais, A., Greillier, L., Audigier-Valette, C., Uwer, L., Hureaux, J., Moro-Sibilot, D., Guisier, F., Carmier, D., Madelaine, J., Otto, J., Souquet, P.-J., Gounant, V., Merle, P., Molinier, O., Renault, A., Rabeau, A., Morin, F., Denis, M. G., & Pujol, J.-L. (2020). Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. Journal of Clinical Medicine, 9(12), 3861. https://doi.org/10.3390/jcm9123861